Abbott Laboratories (FreeStyle Libre)

Abbott's FreeStyle Libre continuous glucose monitoring system is the most widely used CGM globally, with a sensor-based wearable and mobile app for real-time glucose tracking. NYSE: ABT (est. 1888). Libre drives ~$6B in annual diabetes care revenue. Libre 3 received FDA clearance. Lingo OTC CGM for wellness launched 2024. Global installed base exceeds 5M users.

FreeStyle Libre drives the consumer-accessible CGM market and competes directly with DexCom; Abbott's broader diagnostics and medical device portfolio means Libre benefits from unmatched distribution in retail and international markets.

freestyle.abbott Connected Wearables

United Statespublic · ABT

At a glance

Total raised

Undisclosed

no public funding on record

Headcount

10k+

approximate · public range

Headquarters

Abbott Park

United States

Founded

1888

138 years active

Status

Public

Ticker · ABT

Subsector

Connected Wearables

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Founding

50% off

/month

94 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access

Already subscribed? Sign in →

Funding history

Total raised

—

Rounds tracked

No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.

Stock performance

$87.41000366210938

2026-05-22 · ABT

Founder backgrounds

Dr. Wallace C. Abbott

Founder

A graduate of the University of Michigan Medical School (1885), Abbott began practicing medicine in Chicago in 1886 and soon encountered a problem: liquid plant-based medicines varied widely in potency. He adopted a technique developed by Belgian surgeon Adolphe Burggraeve to isolate active alkaloids from medicinal plants into solid, precisely measured "dosimetric granules." In 1888, he began compounding these granules above his People's Drug Store, founding what became the Abbott Alkaloidal Company—later Abbott Laboratories. A physician-first founder, Abbott also served as editor of *The Alkaloidal Clinic*, using his clinical credibility and editorial platform to drive adoption among fellow doctors. His company grew into one of the world's largest healthcare conglomerates and, more than a century later, brought the FreeStyle Libre continuous glucose monitoring system to market.

AI bull / bear

Bull case

Abbott's FreeStyle Libre is the undisputed market leader in continuous glucose monitoring, with over 5 million users and roughly $6 billion in annual diabetes care revenue. That installed base is a compounding moat: every new Libre 3 sensor shipped strengthens Abbott's manufacturing scale and cost advantage against DexCom's G7. Libre 3 earned FDA clearance with best-in-class accuracy and a coin-sized profile that patients prefer, and Abbott's legacy diagnostics and medical device infrastructure gives it retail pharmacy and international distribution no pure-play rival can match. The 2024 launch of Lingo, an over-the-counter CGM for wellness and metabolic health, opens an entirely new addressable market beyond the type 1 and type 2 diabetes populations. If even a fraction of the 100 million US adults with prediabetes or the broader quantified-self movement adopts OTC CGMs, Abbott captures the lion's share of a category it already defines. With Abbott's balance sheet and global footprint, Libre can win the volume game while DexCom fights for premium positioning.

Bear case

Abbott's dominance in CGM is real, but it faces a classic innovator's dilemma in a market racing toward commoditization. DexCom's G7 matches Libre 3 on accuracy and form factor while investing aggressively in direct-to-consumer marketing and connected insulin pump partnerships that Abbott lacks. The Lingo OTC wellness play is a high-stakes gamble: there is no reimbursement code, no clinical guideline, and no evidence yet that healthy adults will pay $49-plus out of pocket every two weeks to track glucose they do not medically need to manage. The predicate condition for CGM growth has always been insurance coverage, and wellness CGMs abandon that engine entirely. Meanwhile, Apple's long-running investment in non-invasive optical glucose sensing threatens to leapfrog the entire needle-and-filament sensor paradigm. If a smartwatch delivers even directional glucose data without a disposable, Abbott's razor-and-blade model loses its durable revenue stream. At $6 billion, the diabetes business is large enough that growth deceleration, not raw contraction, would pressure Abbott's valuation multiple.

Generated by deepseek-v4-pro · May 2, 2026Refreshes quarterly · see disclosures

In the news

Abbott Laboratories (FreeStyle Libre) · last 30 days

No articles ingested yet for Abbott Laboratories (FreeStyle Libre). Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.

Watch

Leadership

Dr. Wallace C. Abbott

Founder

—

Robert B. Ford

Chairman and Chief Executive Officer

—

Philip P. Boudreau

Executive Vice President, Finance and Chief Financial Officer

—

Lisa D. Earnhardt

Executive Vice President and Group President

—

Products

FreeStyle Libre 3
A continuous glucose monitoring (CGM) system that provides real-time glucose readings every minute via a small sensor worn on the back of the upper arm for up to 14 days. Designed for people with diabetes, it eliminates the need for routine fingerstick calibration and transmits glucose data directly to a smartphone app. It is the smallest and thinnest CGM sensor available, featuring optional real-time alerts for high and low glucose levels.
FreeStyle Libre 3 Plus
An enhanced version of the FreeStyle Libre 3 CGM sensor offering extended wear of up to 15 days with real-time glucose readings every minute. It is authorized for use with compatible automated insulin delivery (AID) systems, giving people with diabetes tighter glucose control. The sensor pairs with the Libre mobile app for convenient, scan-free glucose monitoring and trend analysis.
FreeStyle Libre 2
A flash glucose monitoring system that measures glucose levels through a small sensor worn on the upper arm for up to 14 days. Users can scan the sensor with a reader or smartphone to see a real-time glucose reading, an 8-hour history, and a trend arrow. It features optional real-time alarms for low and high glucose, helping people with diabetes manage their condition without routine fingerstick calibration.

Open roles

We don't have a live feed for this company's ATS. Their careers page has every open role.

View all careers ↗